Fecal Incontinence Market Report 2025

The fecal incontinence market size has grown strongly in recent years. It will grow from $2.19 billion in 2024 to $2.34 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to factors such as the rising incidence of injuries or trauma, the increasing prevalence of gastrointestinal disorders, higher healthcare spending, an aging population, the adoption of anti-diarrheal medications, and the expanding availability of treatment and management products.

The fecal incontinence market size is expected to see strong growth in the next few years. It will grow to $3.05 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth during the forecast period can be attributed to factors such as the increasing prevalence of chronic diarrhea, higher demand for minimally invasive procedures, favorable reimbursement policies, the growing popularity of sacral nerve stimulation techniques, and rising investments in research and development. Key trends during this period include technological advancements, the adoption of personalized medicine approaches, a rising demand for biodegradable and eco-friendly products, innovations such as electrical stimulation devices and enhanced absorbent products, and the integration of digital health technologies.

The growing prevalence of gastrointestinal disorders is expected to drive the growth of the fecal incontinence market. Gastrointestinal (GI) disorders affect the digestive system, including the esophagus, stomach, intestines, liver, pancreas, and gallbladder. The increase in these disorders is linked to poor dietary habits and lifestyle changes, such as a high intake of processed foods and low fiber consumption. Conditions such as inflammatory bowel disease (IBD), chronic diarrhea, and irritable bowel syndrome (IBS) can lead to fecal incontinence by disrupting bowel function in various ways. For example, in June 2023, Crohn's and Colitis Canada reported that the number of people living with IBD is projected to grow from 322,600 in 2023 (0.8% of the population) to 470,000 by 2035 (1.1% of the population). Additionally, 11,000 new cases were expected in 2023, with projections increasing to 14,000 new cases by 2035. This rise in gastrointestinal disorders is driving the growth of the fecal incontinence market.

Companies in the fecal incontinence market are developing innovative solutions such as pelvic health systems to improve patient comfort, enhance treatment outcomes, and expand their market presence. A pelvic health system refers to various medical technologies, services, and treatments aimed at diagnosing, managing, and improving the health of pelvic organs and structures. These systems are designed to address pelvic floor conditions, including incontinence, pelvic pain, and reproductive health issues. For example, in June 2023, Axena Health Inc., a US-based medical device company, launched the Leva pelvic health system, which received U.S. Food and Drug Administration clearance. This system offers a non-invasive, drug-free method to strengthen pelvic floor muscles using motion sensors and real-time feedback, guiding users through five-minute daily exercises. With telehealth integration, the system specifically targets fecal incontinence, providing an accessible and effective solution for patients.

In January 2024, Boston Scientific Corporation, a US-based medical technology company, acquired Axonics Inc. for $3.7 billion. This acquisition aims to enhance Boston Scientific’s urology portfolio by incorporating Axonics’ innovative technologies for treating urinary and bowel dysfunction. Axonics specializes in neuromodulation solutions for conditions such as overactive bladder (OAB), fecal incontinence, and urinary retention.

Major players in the fecal incontinence market are 3M Company, Medtronic plc, Medline Industries LP, Essity AB, B. Braun Melsungen AG, Domtar Corporation, Coloplast Corp., HARTMANN Direct, ConvaTec Group plc, Ontex Group NV, Hollister Incorporated, Abena Group, Laborie Medical Technologies, Home Care Delivered, 180 Medical, Attends Healthcare Products Inc., Principle Business Enterprises Inc., Carewell, NorthShore Care Supply, InControl Medical, Tranquility Products, Aeroflow Urology, Reliance Medical Inc., TZMO SA, and Allegro Medical.

North America was the largest region in the fecal incontinence market in 2024. The regions covered in fecal incontinence report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the fecal incontinence market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Fecal incontinence is the involuntary loss of bowel control, resulting in the unintentional passing of stool or gas. It can range from occasional stool leakage while passing gas to a complete inability to control bowel movements. Causes can include damage to muscles or nerves, diarrhea, constipation, or underlying medical conditions such as inflammatory bowel disease or neurological disorders.

The primary product types for managing fecal incontinence include absorbent products, anal inserts, electrical stimulation devices, and other related items. Absorbent products help control fecal incontinence by preventing leaks and providing comfort. These products are used by various age groups, including pediatric, adult, and elderly populations, and are applied in hospitals, clinics, home care environments, and other settings. They are available through a variety of distribution channels, such as online stores, pharmacies, specialty stores, and more.

The fecal incontinence market research report is one of a series of new reports that provides fecal incontinence market statistics, including the fecal incontinence industry global market size, regional shares, competitors with the fecal incontinence market share, detailed fecal incontinence market segments, market trends, and opportunities, and any further data you may need to thrive in the fecal incontinence industry. This fecal incontinence market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fecal incontinence market consists of revenues earned by entities by providing services such as medical treatments, pelvic floor rehabilitation, surgical interventions, consultation, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The fecal incontinence market also includes sales of bowel management systems, anti-diarrheal drugs, laxatives, stool softeners, artificial sphincters, and nerve stimulators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.